Skip to main content
Download PDF

Expression level and clinical significance of NBAT-1 in human cancers: a systematic review and meta-analysis

BMC Cancer volume 24, Article number: 109 (2024) Cite this article

Abstract

Purpose

There is an aberrant expression of NBAT-1 in various human cancers, which was proven to limit the proliferation, invasion, and metastasis of tumour cells via multiple approaches. Most existing research focuses on sample size and discrete outcomes. Thus, a quantitative meta-analysis was performed to elucidate the prognostic value of lncRNA NBAT-1 expression in cancer patients.

Materials and methods

Using Web of Science and PubMed, two researchers independently identified relevant studies to explore the association between the pathological features of human cancers and NBAT-1 expression levels. Then two scholars conducted literature screening according to exclusion criteria and admission criteria, and finally conducted statistical analysis through data extraction with StataSE 12.0.

Results

A total of 12 eligible studies with 1600 patients were included in the meta-analysis eventually. It is indicated that the low expression level of lncRNA NBAT-1 was closely related to distant metastasis [RR = 0.50, 95% CI (0.33, 0.76), and P = 0.00], deep tumour invasion [RR = 0.62, 95% CI (0.49,0.80), and P = 0.00], poor histological grade [RR = 0.68, 95% CI (0.57, 0.81), and P = 0.00], advanced TNM stage [RR = 0.66, 95% CI (0.55, 0.79), and P = 0.00], large tumour volume[RR = 0.72, 95% CI (0.55, 0.93), and P = 0.01], and lymph node metastasis [RR = 0.62, 95% CI (0.46, 0.84), and P = 0.00], suggesting that it may serve as biomarkers for patients with poor prognosis.

Conclusion

Reduced expression of NBAT-1 can predict poor prognosis in several cancers, as found in the meta-analysis, demonstrating that NBAT-1 can serve as a promising prognostic factor of human cancers.

Peer Review reports

Introduction

Cancer is one of the leading causes of death and one of public health barriers that threatens human health worldwide. According to estimates by the World Health Organization (WHO) in 2019, cancer is the first or second leading cause of death in people under 70 years of age in 112 out of 183 countries, while it ranks third or fourth in another 23 countries [1]. In the latest Global Cancer Statistics, it is estimated that there will be 19.3 million new cases and 10 million cancer deaths worldwide in 2020 [1]. Therefore, there is an urgent need to find a new effective biomarker that can be used to predict the prognosis of different types of cancer and improve the survival outcomes of cancer patients.

Over 75% of the genome is activated and transcribed into noncoding RNAs (ncRNAs) and only 2% is transcribed into proteins according to the high-throughput sequencing of the genome and transcriptome [2]. Although the noncoding transcriptome was first regarded as transcriptional noise, increasing research has demonstrated that lncRNAs are essential in the pathological and physiological processes at various levels [3,4,5]. Long noncoding RNAs (lncRNAs) refer to a new heterogeneous category of ncRNAs with a length of over 200 nucleotides. Through chromatin remodelling, histone methylation, genetic imprinting, as well as transcriptional and post-transcriptional regulation, lncRNAs can control gene expression [4, 6]. For instance, in the nucleus, lncRNAs bind to chromatin-modifying complexes, transcription factors, and other DNA-binding proteins, which can lead to epigenetic alterations [7,8,9]. In the cytoplasm, lncRNAs function as miRNA sponges to regulate the translation and degradation of mRNAs [10, 11]. In addition, lncRNAs participate in ubiquitination, phosphorylation, and other protein modifications [12]. A growing body of work has shown that the dysregulation of lncRNA in various cancers is related to various physiological and pathological processes such as tumor cell proliferation, migration, invasion, angiogenesis and tumor progression [13,14,15,16]. LncRNAs have also been evaluated by numerous studies as independent novel biomarkers for cancer diagnosis and prognosis prediction [17,18,19].

NBAT-1 (a lncRNA neuroblastoma-associated transcript-1), which maps to the 6p22 locus, was first identified by Gaurav Kumar Pandey as a biomarker to predict the clinical results of neuroblastoma [20]. There is an aberrant expression of NBAT-1 in various human cancers, which was proven to limit the proliferation, invasion, and metastasis of tumour cells via multiple approaches. We now summarize the potential targets and pathways of NBAT-1 as follows (Table 1).

Table 1 Summary of potential targets and pathways of NBAT-1
Full size table

For nervous system, NBAT1 affects the biological behaviour of tumours through different pathways. In neuroblastoma, NBAT-1 affects target genes relevant to cell invasion and proliferation in epigenetics by acting as a scaffold for EZH2, and by mechanically inhibiting the NRSF/REST pathway the neural differentiation is controlled by it as well [20, 37]. In addition, in neuroblastoma, NBAT-1/CASC15/MYCN/USP36/COL18A1 controls a new oncogenic pathway, as revealed by Prasanna Kumar Juvvuna [21]. Additionally, Sanhita Mitra proved that NBAT-1, which can act as a p53-responsive lncRNA, is resistant to genotoxic drugs by altering CRM1 and MDM2 function, thus accelerating the accumulation of p53 in cytoplasm and the loss from mitochondrial and nuclear compartments [22]. In glioma, the results of a study by Ning Guan suggested that NBAT-1 may up-regulate SOX7 by inhibiting miR-21 to suppress the invasion, migration, and proliferation of glioma cells [23]. Moreover, J. LIU demonstrated that NBAT-1 can affect the prognosis and the malignant degree of gliomas by regulating Akt [24].

NBAT1 plays a similar role in the respiratory system. In lung cancer, as revealed by T. Lei, NBAT-1 is downregulated and can affect the cell cycle and the apoptosis and proliferation of cells by downregulating the expression level of RAC1 [25]. Furthermore, Tianliang Zheng proved that NBAT-1 could inhibit autophagy by interacting with PSMD10 and promoting its degradation. Therefore, in non-small cell lung cancer, it can inhibit the activeness of HSF1 and PSMD10 in the ATG7 promoter, thus inhibiting ATG7 transcription [26].

It has also been reported that NBAT-1 affected gastric cancer, hepatocellular carcinoma and colorectal carcinoma in the digestive system. By enhancing the proteasome-dependent degradation and polyubiquitination of Sox9, NBAT-1 interacts with it to reduce the stability. Also, Sox9 can use the NBAT-1 promoter to suppress its transcription. The suppressive effects of the negative feedback loop of Sox9 and NBAT-1 kept being enhanced [28]. Moreover, via the downregulated expression of PTEN, the growth of gastric cancer can be promoted by the low expression of NBAT-1, as revealed by Yuan Gao [29]. In hepatocellular carcinoma, NBAT-1 suppresses the stability of c-Myc mRNA by binding to IGF2BP1 and inhibiting their interaction, thereby inhibiting tumourigenesis through cell cycle blockade and increased apoptosis [32]. In colorectal carcinoma (CRC), Chen Li proved the inhibition effect of lncRNA NBAT-1 on the development of OXA-resistant CRC cells by suppressing miR-4504 to mediate the WWC3/LATS1/YAP axis [34].

Several studies have revealed the link between NBAT-1 and urinary system. In bladder cancer, Dan Du revealed that NBAT-1 suppressed cell proliferation by the EMT pathway [33]. In renal carcinoma, NBAT-1 takes advantage of the miR-346/GSK-3β axis and inhibits cell migration and proliferation [36].

Additionally, for other systems, NBAT-1 can affect the prognosis of other cancers.—In epithelial ovarian cancer (EOC), Changsheng Yan verified that NBAT-1 acts as an anti-oncogene and can be potentially used in EOC therapy by targeting the ERK1/2 and AKT signalling pathways [31]. According to Chunhua Tian, in endometrial cancer, NBAT-1 can limit the invasion, migration, and proliferation of EC cells and facilitate apoptosis through PTEN regulation using the sponging miR-21-5p [35]. In breast cancer, Pengnan Hu verified that the cell invasion of breast cancer can be inhibited by NBAT-1 through the suppression of the EZH2-induced H3K27me3 of DDK1 mechanically [30]. As a key part of Polycomb Repressive Complex 2 (PRC2), EZH2 is found upregulated in several cancers and is related to epigenetic regulation [38]. In osteosarcoma, Cheng Yang demonstrated that NBAT-1 negatively modulates growth and metastasis, and invasion by physically interacting with miR-21 and then regulating downstream targets of miR-21, which includes RECK, TPM1, PDCD4, and PTEN [27].

It is proved that aberrant NBAT-1 expressions are likely to affect human cancer prognosis. But most existing research focuses on sample size and discrete outcomes. Thus, a quantitative meta-analysis was performed to elucidate the prognostic value of lncRNA NBAT-1 expression in cancer patients.

Methods

Literature search strategies

Using Web of Science and PubMed, two researchers independently identified relevant studies to explore the association between the pathological features of human cancers and NBAT-1 expression levels. The strategy to search literature combined multiple keywords (“cancer or carcinoma or tumour or neoplasm or malignant neoplasm or malignancy”, “NBAT1”, and “NBAT-1”). Together with these, identification of the obtained literature was performed to detect supplementary research works.

Inclusion and exclusion criteria

The involved research should conform with the following inclusion criteria: 1) stated NBAT-1 expression levels according to the quantitative reverse transcription polymerase chain reaction (RT-qPCR); 2) offered the outcomes; 3) used specific standard of NBAT-1 expression levels to categorize patients into subgroups with low expression and high expression; 4) offered data on patients’ clinicopathological attributes, including at least one of the following ones: distant metastasis, histological grade, tumour invasion depth, lymph node metastasis, and TNM stage; 5) it should be a cohort or case–control research.

A study was not considered for analytical purposes if satisfy one of the following exclusion criteria: 1) stated recurring studies or included patients from an earlier research work; 2) did not provide sufficient data detail; 3) used non-human specimens; 4) were reports published in a non-English language; 5) were commentaries, reviews, unpublished data, and letters.

Concerning the exclusion and inclusion criteria, two researchers reviewed the title, abstract, and content of these studies to evaluate the research quality.

Literature screening and data extraction

In the light of the inclusion and exclusion criteria, data were collected by two investigators (Yang Yu and Kedi Fan), and additionally, discrepancies were resolved via discussion or consensus with a third investigator (Yang Yu and Kedi Fan) prior to the analysis. Data derivation from previous research was: year of publication, first author, country of origin, types of cancer, identification method, the aggregate number of patients, number of patients in groups with low and high NBAT-1 expressions, and cut-off NBAT-1 approximate values at multiple expression levels.

Quality assessment

The quality of related research was evaluated by the Newcastle‒Ottawa Scale, whose indexes include selection (4 points), results (3 points), and comparability (2 points), with scores ranging from 0 to 9. Two investigators carried out independent evaluation of the selected studies (Yang Yu and Kedi Fan) by resolving the differences via discussion or consensus with a third investigator (Yang Yu and Kedi Fan). Table 1 shows the score of each and every included research study. The higher the score, the better the methodological quality.

Statistical analysis

Cochran’s and ChiI-square-based Q and I2 tests were employed to examine the heterogeneity of implicated studies. With the significance level of α = 0.1, the homogeneity test was conducted. P values < 0.5 were defined significant, and I2 values > 50% indicated that the studies are heterogeneous. a random effect model was employed for analysis purposes, and a fixed effect model to analyse homogeneous data. Statistical analysis was performed with StataSE 12.0 (Stata Corp LP, College Station, Texas, USA).

Results

Data selection and features

Twelve studies adhered to the inclusion criteria, involving 1600 patients. And all of the studies stemmed from China, wherein 3 studies were about non-small cell lung cancer [25, 26, 39], and the others about neuroblastoma [20], glioblastoma [24], osteosarcoma [27], gastric cancer [28], breast cancer [30], ovarian cancer [31], hepatocellular carcinoma [32], and bladder cancer [33], clear cell renal cell carcinoma [40].

RT qPCR was employed to record the NBAT-1 expression. On this basis, patients were classified into subgroups with low and high NBAT-1 expression. The mean, median, fold-change, and median ratio of relative NBAT-1 expression were used as cut-offs for estimating NBAT-1 expression. Table 2 presents the summaries of the attributes of related research, and the flow chart of the search and selection of research work is shown in Fig. 1.

Table 2 Characteristics of the included studies
Full size table
Fig. 1
figure 1

Flowchart of selecting studies for inclusion

Full size image

Correlation between NBAT-1 expression and pathological features

Age

Eight researches studied the correlation between Age (elderly vs. nonelderly) and the lncRNA NBAT-1 expression. In these studies, there was no statistically significant heterogeneity (P = 0.19, I2 = 30.00%). Therefore, it was not statistically significant to calculate the accumulated pooled RR and its 95% CI by using a fixed effect model [RR = 1.01, 95% CI (0.87,1.17), P = 0.93] (Fig. 2A, Table 3). The outcome suggested that the NBAT-1 expression level was independent of age.

Fig. 2
figure 2

Forest plots for association of NBAT-1 expression with clinicopathological features. A Age. B Gender. C TNM stage. D Lymph node metastasis. E Tumor stage. F Distant Metastasis. G Histological grade. H Tumor size

Full size image
Table 3 Meta-analysis results for the association of NBAT-1 with clinicopathological parameters
Full size table

Gender

The relationship between gender (male vs. female) and NBAT-1 expression was discussed in eight studies, which showed heterogeneity with no statistical significance (P = 0.99, I2 = 0.00%). Consequently, a fixed-effect model was employed to calculate the pooled RR with its 95% CI, resulting in a non-statistically significant outcome [RR = 0.95, 95% CI (0.83,1.08), P = 0.40] (Fig. 2B, Table 3). As revealed by it, the NBAT-1 expression level was independent of gender.

TNM stage

Four studies indicated the link between the TNM stage (III/IV vs. I/II) and lncRNA NBAT-1 expression. No statistically significant heterogeneity (P = 0.75, I2 = 0.00%) was obtained. Accordingly, the pooled RR was calculated with its 95% CI using a fixed effect model, and significant differences were obtained [RR = 0.66, 95% CI (0.55, 0.79), and P = 0.00] (Fig. 2C, Table 3). It is suggested that the advanced TNM stage may appear at a low expression level.

Lymph node metastasis

There was altogether eight research focused on the relationship between lymph node metastasis and NBAT-1 expression, with statistically significant heterogeneity (P = 0.01, I2 = 60.10%). Therefore, the pooled RR with a 95% CI was calculated by a random effect model, and a significant difference [RR = 0.62, 95% CI (0.46, 0.84), and P = 0.00] (Fig. 2D, Table 3) was achieved. As illustrated, the group with low NBAT-1 expression level tended to have a higher risk of lymph node metastasis than the high NBAT-1 expression level group.

Tumour invasion depth (T)

Three studies explored the relationship between the depth of tumour invasion and the expression of NBAT-1 with no statistical significance (P = 0.13, I2 = 50.90%). Accordingly, the application of a random-effect model was made to calculate the pooled RR, with a 95% CI. A significant difference was recorded [RR = 0.62, 95% CI (0.49,0.80), and P = 0.00] (Fig. 2E, Table 3). Compared with the highly expressed NBAT-1 group, the group with NBAT-1 low expression level appeared riskier in deep tumour attack (T2 stage or above).

Distant metastasis

Three studies showed the link between distant metastasis and NBAT-1 expression levels, which indicated heterogeneity with no statistical significance (P = 0.21, I2 = 36.40%). Accordingly, the pooled RR, with its 95% CI, was calculated by using a fixed effect model, and significant differences were obtained [RR = 0.50, 95% CI (0.33, 0.76), and P = 0.00] (Fig. 2F, Table 3). The group with low NBAT-1 expression levels possessed a higher risk of vascular invasion than the group with high NBAT-1 expression levels.

Histological grade

Five studies explored the relationship between histological grade and NBAT-1 expression. In the studies considered, no statistically significant heterogeneity was recorded (P = 0.16, I2 = 39.00%). Therefore, the pooled RR, with its 95% CI, was calculated by using a fixed effect model, and significant differences were obtained [RR = 0.68, 95% CI (0.57, 0.81), and P = 0.00] (Fig. 2G, Table 3). It is indicated that the low expression of NBAT-1 is significantly correlated with the advanced histological grade (poor vs. well/moderate).

Tumour size

A total of nine studies have found a link between tumour size and NBAT-1 expression, with no statistically significant heterogeneity (P = 0.02, I2 = 55.70%). Consequently, the pooled RR, with its 95% CI, was calculated by using a random effect model, and a significant difference was obtained [RR = 0.72, 95% CI (0.55, 0.93), and P = 0.01] (Fig. 2H, Table 3). It is indicated that compared with the group with high NKILA expression level, the group with low NKILA expression level was easily affected by the increased risk of tumour size.

Association between NBAT-1 expression and survival in various cancer types

Eleven studies, which involved 1531 patients were analysed to assess the impact of NBAT-1 expression on OS in multiple kinds of cancers (Table 4). It is revealed that the decreased expression of NBAT-1 indicated that the OS performance of related cancers was weak [pooled HR = 3.38, 95% CI (2.54, 4.50), P = 0.00], with heterogeneity (I2 = 0.00%, P = 0.65) (Fig. 3A). According to different tumours in the nervous system, urinary system, respiratory system, and digestive system (Fig. 3B), the researchers measured the sample size (n ≥ 60 or n < 60) (Fig. 3C), follow-up time (≥ 60 months or < 60 months) (Fig. 3D), and NOS score (NOS scores ≥ 7 or < 7) (Fig. 3E). Compared with the group with high NBAT-1 expression, a statistically significant OS reduction and poor survival rate were discovered in the group with low NBAT-1 expression, as depicted in Table 5.

Table 4 Characteristics of the overall survival of patients in the included studies
Full size table
Fig. 3
figure 3

Relationship between NBAT-1 expression and overall survival. A Forest plots for association of NBAT-1 expression with overall survival. B Subgroup analysis stratified by cancer type. C Subgroup analysis stratified by sample size. D Subgroup analysis stratified by follow-up time. E Subgroup analysis stratified by NOS score

Full size image
Table 5 Subgroup meta-analysis of pooled HRs for OS
Full size table

Assessment of publication bias

As for the publication bias, Egger’s funnel plot was employed in this research. There was no considerable publication bias in Age (P = 0.62), Gender (P = 0.13), TNM stage (P = 0.12), distant metastasis (P = 0.67), lymph node metastasis (P = 0.07), tumour size (P = 0.18), tumour stage (P = 0.34) and original OS (P = 0.72) (Fig. 4). However, considerable publication bias was observed in histological grading analysis (P = 0.03).

Fig. 4
figure 4

Egger’s test for publication bias of results of overall survival (OS)

Full size image

Assessment of sensitivity

To evaluate the stability of the initial OS data, the researcher conducted a sensitivity analysis. The meta-analysis results were robust since when any study was excluded, they remain stable (Fig. 5).

Fig. 5
figure 5

Sensitivity analysis for studies on OS by omitting each study sequentially

Full size image

Discussion

Recently, research indicated that long noncoding RNAs (lncRNAs) are fundamental in diagnosing and treating cancers [41, 42]. Additionally, dysregulation of lncRNAs is related to the development of cancer, due to their ability to regulate alternative splicing and translation, stabilise the host mRNAs in post-transcriptional phenomena, or act as a scaffold or guide to regulate protein-DNA or protein–protein interactions [4,5,6, 43]. These lncRNAs with atypical expression are considered molecular biomarkers that will promote the growth of diagnosis and prognosis strategies for different types of human cancers [44].

This meta-analysis in human cancers was about how the expression level of NBAT-1 influences pathological attributes. There were 1600 patients from 12 studies involved. The fixed effect model was suitable for the analysis of age, gender, TNM stage, tumour invasion depth, distant metastasis and histological grade. Furthermore, random effects were applied for tumour size, and lymph node metastasis. Therefore, the low NBAT-1 expression level group possessed a higher risk of deep tumour invasion, distant metastasis, lymph node metastasis, poorly distinguished histological grade, advanced TNM stage, and large tumour size than the low NBAT-1 expression level group. Furthermore, the NBAT-1 expression level is independent of gender and age.

Nevertheless, this research work contained some limitations: (1) each and every research work included in this study originated from China, excluding patients from other states; (2) due to the relatively small scale of patients registered, the investigated cancer types were incomprehensive; (3) consensus failed to be reached on the cut-off approximated in order to distinguish between the groups with low or high NBAT-1 expression level; (4) there was no cohort research work satisfying the inclusion criteria. Therefore, to validate the results, high-quality research with a considerable sample size is required.

Briefly, the low expression level of lncRNA NBAT-1 had a close association with distant metastasis, deep tumour invasion, lymph node metastasis, poorly distinguished histological grade, advanced TNM stage, and large tumour size, suggesting that it may serve as a biomarker for cancer patients with poor prognosis.

Conclusion

As discovered in this meta-analysis, reduced expression of NBAT-1 can predict poor prognosis in several cancers, demonstrating that NBAT-1 can serve as a promising prognostic factor of human cancers. AND the low expression level of lncRNA NBAT-1 had a close association with distant metastasis, deep tumour invasion, lymph node metastasis, poorly distinguished histological grade, advanced TNM stage, and large tumour size, suggesting that it may serve as a biomarker for cancer patients with poor prognosis Nevertheless, so far, it remains crucial to conduct better-designed studies with larger scales to confirm our findings.

Availability of data and materials

All data generated or analysed during this study are included in this published article.

Abbreviations

ncRNAs:

Noncoding RNAs

lncRNAs:

Long noncoding RNAs

CRC:

Colorectal carcinoma

EOC:

Epithelial ovarian cancer

PRC2:

Polycomb Repressive Complex 2

RT-qPCR:

Quantitative reverse transcription polymerase chain reaction

NOS:

The Newcastle–Ottawa Scale

OS:

Overall survival

References

  1. Sung H, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.

    Article  PubMed  Google Scholar 

  2. Bridges MC, Daulagala AC, Kourtidis A. LNCcation: lncRNA localization and function. J Cell Biol. 2021;220(2):e202009045.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Tripathi V, et al. The nuclear-retained noncoding RNA MALAT1 regulates alternative splicing by modulating SR splicing factor phosphorylation. Mol Cell. 2010;39(6):925–38.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Sun W, et al. Regulatory mechanisms of long noncoding RNAs on gene expression in cancers. Cancer Genet. 2017;216–217:105–10.

    Article  PubMed  Google Scholar 

  5. Batista PJ, Chang HY. Long noncoding RNAs: cellular address codes in development and disease. Cell. 2013;152(6):1298–307.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Zhang J, et al. Exosomal long noncoding RNAs are differentially expressed in the Cervicovaginal lavage samples of cervical cancer patients. J Clin Lab Anal. 2016;30(6):1116–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Yu Y, et al. Long non-coding RNA PVT1 promotes cell proliferation and migration by silencing ANGPTL4 expression in cholangiocarcinoma. Mol Ther Nucleic Acids. 2018;13:503–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Li DQ, et al. Tumor suppressive lncRNA MEG3 binds to EZH2 and enhances CXCL3 methylation in gallbladder cancer. Neoplasma. 2022;69(3):538–49.

    Article  CAS  PubMed  Google Scholar 

  9. Yang LH, et al. LncRNA ANRIL promotes multiple myeloma progression and bortezomib resistance by EZH2-mediated epigenetically silencing of PTEN. Neoplasma. 2021;68(4):788–97.

    Article  CAS  PubMed  Google Scholar 

  10. Shao Y, et al. LncRNA-RMRP promotes carcinogenesis by acting as a miR-206 sponge and is used as a novel biomarker for gastric cancer. Oncotarget. 2016;7(25):37812–24.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Zhao J, et al. lncRNA LIFR-AS1 inhibits gastric carcinoma cell proliferation, migration and invasion by sponging miR-4698. Mol Med Rep. 2021;23(2):153.

    Article  CAS  PubMed  Google Scholar 

  12. Chen J, Liu S, Hu X. Long non-coding RNAs: crucial regulators of gastrointestinal cancer cell proliferation. Cell Death Discov. 2018;4:50.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Feng J, et al. LncRNA PCNAP1 modulates hepatitis B virus replication and enhances tumor growth of liver cancer. Theranostics. 2019;9(18):5227–45.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Yan H, et al. LncRNA FLVCR1-AS1 mediates miR-513/YAP1 signaling to promote cell progression, migration, invasion and EMT process in ovarian cancer. J Exp Clin Cancer Res. 2019;38(1):356.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Zeng Z, et al. LncRNA-MTA2TR functions as a promoter in pancreatic cancer via driving deacetylation-dependent accumulation of HIF-1alpha. Theranostics. 2019;9(18):5298–314.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Geisler S, Coller J. RNA in unexpected places: long non-coding RNA functions in diverse cellular contexts. Nat Rev Mol Cell Biol. 2013;14(11):699–712.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Yang F, et al. Up-regulated long non-coding RNA H19 contributes to proliferation of gastric cancer cells. FEBS J. 2012;279(17):3159–65.

    Article  CAS  PubMed  Google Scholar 

  18. Chi Y, et al. Long non-coding RNA in the pathogenesis of cancers. Cells. 2019;8(9):1015.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. GhahramaniAlmanghadim H, et al. New insights into the importance of long non-coding RNAs in lung cancer: future clinical approaches. DNA Cell Biol. 2021;40(12):1476–94.

    Article  CAS  Google Scholar 

  20. Pandey GK, et al. The risk-associated long noncoding RNA NBAT-1 controls neuroblastoma progression by regulating cell proliferation and neuronal differentiation. Cancer Cell. 2014;26(5):722–37.

    Article  CAS  PubMed  Google Scholar 

  21. Juvvuna PK, et al. NBAT1/CASC15–003/USP36 control MYCN expression and its downstream pathway genes in neuroblastoma. Neurooncol Adv. 2021;3(1):vdab056.

    PubMed  PubMed Central  Google Scholar 

  22. Mitra S, et al. Subcellular distribution of p53 by the p53-responsive lncRNA NBAT1 determines chemotherapeutic response in neuroblastoma. Cancer Res. 2021;81(6):1457–71.

    Article  CAS  PubMed  Google Scholar 

  23. Guan N, et al. Long non-coding RNA NBAT1 inhibits the progression of glioma through the miR-21/SOX7 axis. Oncol Lett. 2020;20(3):3024–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Liu J, et al. Effect of downregulated lncRNA NBAT1 on the biological behavior of glioblastoma cells. Eur Rev Med Pharmacol Sci. 2018;22(9):2715–22.

    CAS  PubMed  Google Scholar 

  25. Lei T, et al. LncRNA NBAT-1 is down-regulated in lung cancer and influences cell proliferation, apoptosis and cell cycle. Eur Rev Med Pharmacol Sci. 2018;22(7):1958–62.

    CAS  PubMed  Google Scholar 

  26. Zheng T, et al. Long noncoding RNA NBAT1 inhibits autophagy via suppression of ATG7 in non-small cell lung cancer. Am J Cancer Res. 2018;8(9):1801–11.

    CAS  PubMed  PubMed Central  Google Scholar 

  27. Yang C, et al. Long noncoding RNA NBAT1 negatively modulates growth and metastasis of osteosarcoma cells through suppression of miR-21. Am J Cancer Res. 2017;7(10):2009–19.

    CAS  PubMed  PubMed Central  Google Scholar 

  28. Yan J, et al. A negative feedback loop between long noncoding RNA NBAT1 and Sox9 inhibits the malignant progression of gastric cancer cells. Biosci Rep. 2018;38(6):BSR20180882.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Gao Y, Chen J. Low expression of lncRNA NBAT-1 promotes gastric cancer development and is associated with poor prognosis. J BUON. 2019;24(2):656–62.

    PubMed  Google Scholar 

  30. Hu P, et al. NBAT1 suppresses breast cancer metastasis by regulating DKK1 via PRC2. Oncotarget. 2015;6(32):32410–25.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Yan C, et al. Long noncoding RNA NBAT-1 suppresses tumorigenesis and predicts favorable prognosis in ovarian cancer. Onco Targets Ther. 2017;10:1993–2002.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Wei L, et al. Long noncoding RNA NBAT1 suppresses hepatocellular carcinoma progression via competitively associating with IGF2BP1 and decreasing c-Myc expression. Hum Cell. 2021;34(2):539–49.

    Article  CAS  PubMed  Google Scholar 

  33. Du D, et al. Decreased expression of long noncoding RNA NBAT1 indicates a poor prognosis and promotes cell proliferation and EMT in bladder cancer. Int J Clin Exp Med. 2017;10(6):9214–21.

    Google Scholar 

  34. Li C, Li X. Antitumor activity of lncRNA NBAT-1 via inhibition of miR-4504 to target to WWC3 in oxaliplatin-resistant colorectal carcinoma. J Healthc Eng. 2022;2022:9121554.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Tian C, et al. lncRNA NBAT1 inhibits cell metastasis and promotes apoptosis in endometrial cancer by sponging miR-21-5p to regulate PTEN. Comput Math Methods Med. 2022;2022:9304392.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Xue S, et al. LncRNA NBAT1 suppresses cell proliferation and migration via miR-346/GSK-3beta axis in renal carcinoma. IUBMB Life. 2019;71(11):1720–8.

    Article  CAS  PubMed  Google Scholar 

  37. Pandey GK, Kanduri C. Long noncoding RNAs and neuroblastoma. Oncotarget. 2015;6(21):18265–75.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Yu Y, et al. Long noncoding RNA ANRIL promotes the malignant progression of cholangiocarcinoma by epigenetically repressing ERRFI1 expression. Cancer Sci. 2020;111(7):2297–309.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Wang DL, Yuan P, Tian JY. Expression of long noncoding RNA NBAT1 is associated with the outcome of patients with non-small cell lung cancer. Rev Assoc Med Bras (1992). 2020;66(7):898–903.

    Article  PubMed  Google Scholar 

  40. Xue S, et al. Decreased expression of long non-coding RNA NBAT-1 is associated with poor prognosis in patients with clear cell renal cell carcinoma. Int J Clin Exp Pathol. 2015;8(4):3765–74.

    PubMed  PubMed Central  Google Scholar 

  41. Tan YT, et al. LncRNA-mediated posttranslational modifications and reprogramming of energy metabolism in cancer. Cancer Commun (Lond). 2021;41(2):109–20.

    Article  PubMed  Google Scholar 

  42. Li J, et al. Regulation of lncRNA and its role in cancer metastasis. Oncol Res. 2016;23(5):205–17.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Liu HT, et al. lncRNA THAP7-AS1, transcriptionally activated by SP1 and post-transcriptionally stabilized by METTL3-mediated m6A modification, exerts oncogenic properties by improving CUL4B entry into the nucleus. Cell Death Differ. 2022;29(3):627–41.

    Article  CAS  PubMed  Google Scholar 

  44. Bhan A, Soleimani M, Mandal SS. Long noncoding RNA and cancer: a new paradigm. Cancer Res. 2017;77(15):3965–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

This study was supported by the Project of Nantong Municipal Health Commission (MB2021042), Nantong Young Medical Key Talents (RC202120) and the Project of Nantong Science and Technology Plan (MS22021035).

Funding

This study was supported in part by grants from the Project of Nantong Municipal Health Commission (MB2021042), Nantong Young Medical Key Talents (RC202120) and the Project of Nantong Science and Technology Plan (MS22021035).

Author information

Author notes

  1. Yang Yu and Kedi Fan contributed equally to this work.

Authors and Affiliations

  1. Department of Oncology, Affiliated Tumour Hospital of Nantong University, Nantong, Jiangsu Province, People’s Republic of China

    Yang Yu, Tingting Ni, Xun Lei Zhang, Xiaoqin Su & Lei Yang

  2. Department of Medical School, Nantong University, Nantong, Jiangsu Province, People’s Republic of China

    Kedi Fan

Authors
  1. Yang Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kedi Fan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tingting Ni
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xun Lei Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Xiaoqin Su
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Lei Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Yang Lei designed the topic of the article. Yang Yu and Kedi Fan extracted, analyzed the data and wrote the main manuscript text. Tingting Ni checked the data. Xunlei Zhang prepared Figs. 4 and 5. Xiaoqin Su prepared Table 5. All authors reviewed the manuscript.

Corresponding author

Correspondence to Lei Yang.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yu, Y., Fan, K., Ni, T. et al. Expression level and clinical significance of NBAT-1 in human cancers: a systematic review and meta-analysis. BMC Cancer 24, 109 (2024). https://doi.org/10.1186/s12885-023-11770-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12885-023-11770-w

Keywords

BMC Cancer

ISSN: 1471-2407

Contact us